• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Unproven Treatments

Background

Because there is no cure for ALS/MND, and approved treatments have a limited effect, people diagnosed with the disease may seek out options that are not offered by their physician. Determining the difference between true and false information regarding ALS treatments can be difficult.

The internet has many websites that promote effective ALS treatments for purchase. Often they are well designed, boast treatments available for multiple diseases and ailments, and provide reassurance through online testimonials from previous clients. In nearly all of these cases, there is no evidence of safety, and in none has a benefit been shown in rigorous scientific studies. Furthermore, these treatments are often extremely expensive, and they are marketed to people who are looking for options. Many people with ALS spend critical life savings or raise funds through family and friends for an opportunity to save their life.

Unproven treatments are sometimes called alternative or off-label treatments. Examples include, but are not limited to: stem cell clinics; holistic, naturopathic, homeopathic, and traditional medicine; and dietary or physical therapy regimens.

Resources like ALSUntangled can be valuable for balanced, open-access information about such alternative treatments, and ClinicalTrials.gov is a resource for determining whether a particular treatment is being tested in a legitimate clinical trial.

The ALSUntangled article “Ten red flags”—things to be wary of in alternative or off-label products—provides a helpful guide to the warning signs to look out for in an advertised potential treatment. Read the “Ten red flags” article.

Recommendation

The SAC recommends that Alliance members defer all medical advice regarding unapproved, unproven, or off-label treatments to an individual’s own clinician. This may be accompanied by objective information about the specific treatment, which may be provided by the SAC. Providing links to resources like ALSUntangled and clinical trials databases like ClinicalTrials.gov is encouraged. Accompanying information can be especially important in situations where an individual does not have access to an ALS specialist physician, and it may assist their clinician in making a medical recommendation. It can also be important to relay that there are thousands of researchers around the world who are dedicated to understanding ALS and finding effective treatments, and if there were anything, anywhere, that actually worked, we would know and we would do everything we could to get it to people living with the disease as soon as possible.

International Alliance of ALS/MND Associations
June 2020


The original language of communication is English, and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • David Solomon, UK

    David Solomon, UK

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Andrew Langat, Kenya

    Andrew Langat, Kenya

  • Anthony Lynch, Australia

    Anthony Lynch, Australia

  • Steve

    Steve

  • Liam Dwyer, England

    Liam Dwyer, England

  • Jon Newsome, USA

    Jon Newsome, USA

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

  • Anderson Custodio Pinto, Brazil

    Anderson Custodio Pinto, Brazil

  • Andrietta, Italy

    Andrietta, Italy
    Andrietta

  • Juvenal Bayona Romero, Colombia

    Juvenal Bayona Romero, Colombia

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Daniel Hare, USA

    Daniel Hare, USA

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Claudette Sturk, Canada

    Claudette Sturk, Canada
    Picture2

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Osiel Mendoza, USA

    Osiel Mendoza, USA

  • Susan Keldani, USA

    Susan Keldani, USA

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • Alex, Argentina

    Alex, Argentina

  • Ailsa Malcolm-Hutton, UK

    Ailsa Malcolm-Hutton, UK

  • Jean Waters, UK

    Jean Waters, UK

  • Glen Elison, USA

    Glen Elison, USA

  • Rudiger Hanemann, Germany

    Rudiger Hanemann, Germany

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • Shaleen Latchman, Canada

    Shaleen Latchman, Canada

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Willi Klein, UK

    Willi Klein, UK

  • Anita Forte, USA

    Anita Forte, USA

  • Jay Epstein, USA

    Jay Epstein, USA

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Richard Clark, New Zealand

    Richard Clark, New Zealand

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Elkin Ramiro Gaviria Muñoz, Colombia

    Elkin Ramiro Gaviria Muñoz, Colombia

  • Yolanda Armendariz, Mexico

    Yolanda Armendariz, Mexico

  • Den Haag, Netherlands

    Den Haag, Netherlands

  • Alejandro Aquino, Argentina

    Alejandro Aquino, Argentina

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login